STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening-Reference-Cited by-同舟云学术

STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening

Published:2018-08-02 Issue:1 Volume:25 Page:
ISSN:1423-0127
Container-title:Journal of Biomedical Science
language:en
Short-container-title:J Biomed Sci

Author:

Cheng Chun-Chia,Liao Po-Nien,Ho Ai-Sheng,Lim Ken-Hong,Chang Jungshan,Su Ying-Wen,Chen Caleb Gon-Shen,Chiang Ya-Wen,Yang Bi-Ling,Lin Huan-Chau,Chang Yu-Cheng,Chang Chun-Chao,Chang Yi-Fang

Funder

Ministry of Science and Technology, Taiwan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Biochemistry, medical,Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12929-018-0456-y.pdf

Reference50 articles.

1. New Guideline on Managing Colorectal Cancer. Cancer discovery. 2017;7(4):OF2.

2. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual inhibition of EGFR and c-Src by Cetuximab and Dasatinib combined with FOLFOX chemotherapy in patients with metastatic colorectal Cancer. Clin Cancer Res. 2017;23(15):4146–54.

3. Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferrau F, Labianca R, Ronzoni M, Scartozzi M, Galli F. Investigators G. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: an Italian Group for the Study of gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. Eur J Cancer. 2017;83:106–15.

4. Zhao Y, Peng J, Zhang E, Jiang N, Li J, Zhang Q, Zhang X, Niu Y. CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis. Oncotarget. 2016;7(9):10023–36.

5. Choi JE, Bae JS, Kang MJ, Chung MJ, Jang KY, Park HS, Moon WS. Expression of epithelial-mesenchymal transition and cancer stem cell markers in colorectal adenocarcinoma: Clinicopathological significance. Oncol Rep. 2017;38(3):1695–705.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies;Environmental Research;2023-09

2. Molecular Mechanisms Underlying Pluripotency and Self-Renewal of Embryonic Stem Cells;International Journal of Molecular Sciences;2023-05-07

3. STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo;Cancers;2023-04-11

4. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target;Molecular Cancer;2022-07-14

5. SCAMP3 Regulates EGFR and Promotes Proliferation and Migration of Triple-Negative Breast Cancer Cells through the Modulation of AKT, ERK, and STAT3 Signaling Pathways;Cancers;2022-06-05